Enrollment complete in lead-in portion of eravacycline trial

|By:, SA News Editor

Tetraphase Pharmaceuticals (TTPH) completes patient enrollment in the lead-in portion of its Phase 3 clinical trial evaluating the safety and efficacy of eravacycline for the treatment of complicated urinary tract infections. The lead-in section's purpose is to inform the selection of an oral dose to take forward into the pivotal portion of the trial.

The company expects to report top-line data in Q3.